Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer
LOS ANGELES, Dec. 16, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the award of a new $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The award evaluates the combination of Trethera's lead drug […]